Expression of c-erbB-2 and p53 in breast carcinoma patients: Comparison with traditional prognostic factors and survival

Journal of International Medical Research

Volumn 32, Issue 5, 2004, Pages 455-464

  Gurkan, A ^a   Erdogan, G ^b   Erdogan, O ^a   Pestereli, E ^b   Ogus, M ^a   Karaveli, S ^b   Colak, Taner ^a  

^a Akdeniz Medical Microbiology Department University School of Medicine   (Turkey)

^b AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Breast cancer; C erbB 2; Disease relapse; p53; Prognostic factors

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53; THYROID HORMONE RECEPTOR BETA;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER GRADING; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; DISEASE ASSOCIATION; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION;

EID: 4544311702     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000403200502     Document Type: Article

References (26)

1. Carter CL, Allen C, Henson DE: Relation of tumor size, lymph node status and survival in 24740 breast cancer cases. Cancer 1989; 63: 181-187.
2. Bloom HJ, Richardson WW: Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957; 11: 359-377.
3. Jatoi I, Hilsenbeck SG, Clark GM, Osborne CK: Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol 1999; 17: 2334-2340.
4. Valagussa P, Bonadonna G, Veronesi U: Patterns of relapse and survival following radical mastectomy. Analysis of 716 consecutive patients. Cancer 1978; 41: 1170-1178.
5. Revillion F, Bonneterre J, Peyrat JP: ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 1998; 34: 791-808.
6. Zellars RC, Hilsenbeck SG, Clark GM, Allred DC, Herman TS, Chamness GC, et al: Prognostic value of p53 for local failure in mastectomy-treated breast cancer patients. J Clin Oncol 2000; 18: 1906-1913.
7. Caleffi M, Teague MW, Jensen RA, Vnencak-Jones CL, Dupont WD, Parl FF: p53 gene mutations and steroid receptor status in breast cancer. Clinicopathologic correlations and prognostic assessment. Cancer 1994; 73: 2147-2156.
8. Charpin C, DeVictor B, Andrac L, Amabile J, Bergeret D, LaVaut MN, et al: p53 quantitative immunocytochemical analysis in breast carcinomas. Hum Pathol 1995; 26: 159-166.
9. Molina R, Segui MA, Climent MA, Bellmunt J, Albanelll J, Fernandez M, et al: p53 oncoprotein as a prognostic indicator in patients with breast cancer. Anticancer Res 1998; 18: 507-511.
10. Pietilainen T, Lipponen P, Aaltomaa S, Eskelinen M, Kosma VM, Syrjanen K: Expression of p53 protein has no independent prognostic value in breast cancer. J Pathol 1995; 177: 225-232.
11. O'Reilly SM, Barnes DM, Camplejohn RS, Bartkova J, Gregory WM, Richards MA: The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. Br J Cancer 1991; 63: 444-446.
12. Marks JR, Humphrey PA, Wu K, Berry D, Bandarenko N, Kerns BJ, et al: Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. Ann Surg 1994; 219: 332-341.
13. Yildirim E, Dalgic T, Berberoglu U: Prognostic significance of young age in breast cancer. J Surg Oncol 2000; 74: 267-272.
14. Bertheau P, Steinberg SM, Merino MJ: C-erbB-2, p53 and nm23 gene product expression in breast cancer in young women: immunohistochemical analysis and clinicopathologic correlation. Hum Pathol 1998; 29: 323-329.
15. Schroeter CA, De Potter CR, Rathsmann K, Willighagen RG, Greep JC: c-erbB-2 positive breast tumours behave more aggressively in the first years after diagnosis. Br J Cancer 1992; 66: 728-734.
16. Fisher B, Redmond C, Fisher ER, Caplan R: Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 1988; 6: 1076-1087.
17. Clark GM, Osborne CK, McGuire WL: Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol 1984; 2: 1102-1109.
18. Winstanley J, Cooke T, George WD, Murray G, Holt S, Croton R, et al: The long term prognostic significance of oestrogen receptor analysis in early carcinoma of the breast. Br J Cancer 1991; 64: 99-101.
19. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, et al: Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124: 966-978.
20. Mirza AN, Mirza NQ, Vlastos G, Singletary SE: Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg 2002; 235: 10-26.
21. Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, et al: Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 1990; 8: 103-112.
22. Zhou DJ, Ahuja H, Cline MJ: Proto-oncogene abnormalities in human breast cancer: c-ERBB-2 amplification does not correlate with recurrence of disease. Oncogene 1989; 4: 105-108.
23. Reed W, Hannisdal E, Boehler PJ, Gundersen S, Host H, Marthin J: The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14 - 30 years. Cancer 2000; 88: 804-813.
24. Haerslev T, Jacobsen GK: An immunohistochemical study of p53 with correlations to histopathological parameters, c-erbB-2, proliferating cell nuclear antigen, and prognosis. Hum Pathol 1995; 26: 295-301.
25. Sawan A, Randall B, Angus B, Wright C, Henry JA, Ostrowski J, et al: Retinoblastoma and p53 gene expression related to relapse and survival in human breast cancer: an immunohistochemical study. J Pathol 1992; 168: 23-28.
26. Barnes DM, Dublin EA, Fisher CJ, Levison DA, Millis RR: Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum Pathol 1993; 24: 469-476.